Literature DB >> 9222603

Identification of the C-terminal region of 70 kDa heat shock protein from Leishmania (Viannia) braziliensis as a target for the humoral immune response.

A G Amorim1, M Carrington, M A Miles, D C Barker, M L de Almeida.   

Abstract

A Leishmania (Viannia) braziliensis (Lb) promastigote cDNA library in lambda gt11 was screened with patients' sera with the aim of identifying antigens specifically related to mucocutaneous leishmaniasis (MCL). One of the clones isolated, 133P, consistently reacted with MCL sera; it was sequenced and found to encode the C-terminal three-quarters of a protein belonging to the highly conserved Hsp70 family. Since Hsp70 proteins from different species tend to be less conserved through the C-terminal end, it was predicted that this region would be more antigenic and was likely to bear the discriminatory epitopes. In order to test this hypothesis, the N- and C-terminal halves of the polypeptide encoded by 133P, 133P-N and 133P-C, respectively, were expressed in Escherichia coli. Immunoblotting analysis demonstrated that 133P-C reacted more strongly with a pool of MCL sera than 133P-N, and both recombinant proteins reacted faintly with pools of cutaneous (CL) and visceral (VL) leishmaniasis sera. These results confirmed the predicted epitope location in the C-terminal region. The 133P-C fragment was also expressed as a fusion protein with glutathione-S-transferase (GST-133P-C), affinity-purified with glutathione-agarose and tested by ELISA with individual sera. From 46 Lb-infected patients, 41 sera (89%) were positive, no cross-reactivity was observed with healthy, Trypanosoma cruzior L. amazonensis-infected individuals. Despite a relatively high cross-reactivity with VL sera, the enhanced humoral response of MCL as compared with CL patients might be interesting for studies on disease aggravation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9222603      PMCID: PMC248477          DOI: 10.1379/1466-1268(1996)001<0177:iotctr>2.3.co;2

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  6 in total

Review 1.  Diagnosis of visceral leishmaniasis: developments over the last decade.

Authors:  Gurumurthy Srividya; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2011-11-09       Impact factor: 2.289

2.  The use of an excreted superoxide dismutase in an ELISA and Western blotting for the diagnosis of Leishmania (Leishmania) infantum naturally infected dogs.

Authors:  C Marín; S S Longoni; H Mateo; J A de Diego; J M Alunda; G Minaya; M Sánchez-Moreno
Journal:  Parasitol Res       Date:  2007-05-12       Impact factor: 2.289

Review 3.  Role of heat shock proteins in protection from and pathogenesis of infectious diseases.

Authors:  U Zügel; S H Kaufmann
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

4.  The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection.

Authors:  Ana M Montalvo-Alvarez; Cristina Folgueira; Javier Carrión; Lianet Monzote-Fidalgo; Carmen Cañavate; Jose M Requena
Journal:  J Biomed Biotechnol       Date:  2008

5.  Recombinant Leishmania infantum heat shock protein 83 for the serodiagnosis of cutaneous, mucosal, and visceral leishmaniases.

Authors:  Beatriz Julieta Celeste; Maria Carmen Arroyo Sanchez; Eduardo Milton Ramos-Sanchez; Luiz Guilherme M Castro; Francisco Assis Lima Costa; Hiro Goto
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

6.  Immunoproteomic Identification and Characterization of Leishmania Membrane Proteins as Non-Invasive Diagnostic Candidates for Clinical Visceral Leishmaniasis.

Authors:  Sarfaraz Ahmad Ejazi; Anirban Bhattacharyya; Somsubhra Thakur Choudhury; Sneha Ghosh; Abdus Sabur; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.